The herpesvirus saimiri ORF 73 regulatory region provides long-term transgene expression in human carcinoma cell lines

Cancer Gene Therapy

Volumn 10, Issue 1, 2003, Pages 49-56

  Giles, Mathew S ^a   Smith, Peter G ^a   Coletta, P Louise ^a   Hall, Kersten T ^a   Whitehouse, Adrian ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Long term expression; Regulatory region; Viral vector

Indexed keywords

GREEN FLUORESCENT PROTEIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CELL ASSAY; CELL LINE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSFECTION; HERPES VIRUS SAIMIRI; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY MECHANISM; TRANSGENE;

ADENOCARCINOMA; ANIMALS; BLOTTING, SOUTHERN; CELL DIVISION; CHLORAMPHENICOL O-ACETYLTRANSFERASE; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HERPESVIRUS 2, SAIMIRIINE; HUMANS; LUMINESCENT PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; OPEN READING FRAMES; PLASMIDS; PROMOTER REGIONS (GENETICS); REGULATORY SEQUENCES, NUCLEIC ACID; TRANSFECTION; TRANSGENES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

ANIMALIA; HERPES; HERPESVIRIDAE; SAIMIRI; SAIMIRIINE HERPESVIRUS 2;

EID: 0037273855     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700523     Document Type: Article

References (42)

1. Hammerschmidt W. Herpesvirus vectors come of age. Curr Opin Mol Ther. 2000;2:532-539.
2. Coffin RS, Latchman DS. Herpes simplex virus-based vectors. In: Latchman DS, ed. Genetic Manipulation of the Nervous System. London: Academic Press; 1996:99-111.
3. Glorioso JC, DeLuca NA, Fink DJ. Development and application of herpes simplex virus vectors for human gene therapy. Annu Rev Microbiol. 1995;49:675-710.
4. Lachmann RH, Efstathiou S. Gene transfer with herpes simplex vectors. Curr Opin Mol Ther. 1999;1:622-632.
5. Krisky DM, Wolfe D, Goins WF, et al. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther. 1998;5:1593-1603.
6. Samaniego LA, Neiderhiser L, DeLuca NA. Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J Virol. 1998;72:3307-3320.
7. Kieff E. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Howley PM, et al, eds. Fields Virology, 3rd ed. Philadelphia: Lippincott-Raven Publishers; 1996:2343-2396.
8. Yates J, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature. 1985;313:812-815.
9. Cotter MA, Robertson ES. Molecular genetic analysis of herpesviruses and their potential use as vectors for gene therapy applications. Curr Opin Mol Ther. 1999;1:633-644.
10. Wade-Martins R, White RE, Kimura H, et al. Stable correction of a genetic deficiency in human cells by an episome carrying a 115 Kb genomic transgene. Nat Biotechnol. 2000;18:1311-1314.
11. Fleckenstein B, Desrosiers RC. Herpesvirus saimiri and herpesvirus alleles. In: Roizman B, ed. The Herpesviruses. vol. 1. New York: Plenum; 1982:253-332.
12. Fickenscher H, Fleckenstein B. Herpesvirus saimiri. Philos Trans R Soc Lond. 2001;356:545-567.
13. Desrosiers RC, Bakker A, Kamine J, et al. A region of the Herpesvirus saimiri genome required for oncogenicity. Science. 1985;228:184-187.
14. Grassmann R, Fleckenstein B. Selectable recombinant herpesvirus saimiri is capable of persisting in a human cell line. J Virol. 1989;63:1818-1821.
15. Simmer B, Alt M, Buckreus I, et al. Persistence of selectable herpesvirus saimiri in various human haematopoietic and epithelial cell lines. J Gen Virol. 1991;72:1953-1958.
16. Stevenson AJ, Cooper M, Griffiths JC, et al. Assessment of herpesvirus saimiri as a potential human gene therapy vector. J Med Virol. 1999;57:269-277.
17. Hall KT, Giles MS, Goodwin DJ, et al. Analysis of gene expression in a human cell line stably transduced with herpesvirus saimiri. J Virol. 2000;74:7331-7337.
18. Smith PG, Coletta PL, Markham AF, Whitehouse A. In vivo episomal maintenance of a herpesvirus saimiri-based gene delivery vector. Gene Ther. 2001;8:1762-1769.
19. Hiller C, Wittmann S, Slavin S, Fickenscher H. Functional long-term thymidine kinase suicide gene expression in human T cells using a herpesvirus saimiri vector. Gene Ther. 2000;7:664-674.
20. Hiller C, Tamguney G, Stolte N, et al. Herpesvirus saimiri pathogenicity enhanced by thymidine kinase of herpes simplex virus. Virology. 2000;278:445-455.
21. Stevenson AJ, Clarke D, Meredith DM, et al. Herpesvirus saimiri-based gene therapy vectors maintain heterologous expression throughout mouse embryonic stem cell differentiation in vitro. Gene Ther. 2000;7:464-471.
22. Bestor TH. Gene silencing as a threat to the success of gene therapy. J Clin Invest. 2000;105:409-411.
23. Glorioso JC, DeLuca NA, Fink DJ. Development and application of herpes simplex virus vectors for human gene therapy. Annu Rev Microbiol. 1995;49:675-710.
24. Fink DJ, Glorioso JC. Herpes simplex virus-based vectors: problems and some solutions. Adv Neurol. 1997;72:149-156.
25. Stevens JG, Wagner EK, Devi-Rao GB, et al. RNA complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons. Science. 1987;235:1056-1059.
26. Wagner EK, Bloom DC. Experimental investigation of herpes simplex virus latency. Clin Microbiol Rev. 1997;10:419-443.
27. Lachmann RH, Efstathiou S. Utilisation of the herpes simplex virus type-1 latency associated regulatory region to drive stable reporter gene expression in the nervous system. J Virol. 1997;71:3197-3207.
28. Smith C, Lachmann RH, Efstathiou S. Expression from the herpes simplex virus type 1 latency-associated promoter in the murine central nervous system. J Gen Virol. 2000;81:649-662.
29. Palmer JA, Branston RH, Lilley CE, et al. Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system. J Virol. 2000;74:5604-5618.
30. Albrecht JC, Nicholas J, Biller D, et al. Primary structure of the herpesvirus saimiri genome. J Virol. 1992;66:5047-5058.
31. Stevenson AJ, Frolova-Jones E, Hall KT, et al. A Herpesvirus saimiri-based gene therapy vector with potential for use in cancer immunotherapy. Cancer Gene Ther. 2000;7:1077-1085.
32. Bird A. The essentials of DNA methylation. Cell. 1992;70:5-8.
33. Kronberg RD, Lorch Y. Chromatin-modifying and remodeling complexes. Curr Opin Genet Dev. 1999;9:148-151.
34. Honess RW, Gompels UA, Barrell BG, et al. Deviations from expected frequencies of CpG dinucleotides in herpesvirus DNAs may be diagnostic of differences in the states of their latent genomes. J Gen Virol. 1989;70:837-855.
35. Kass SU, Landsberger N, Wolffe AP. DNA methylation directs a time dependent repression of transcription initiation. Curr Biol. 1997;7:157-165.
36. Barlow BP. Methylation and imprinting: from host defence to gene regulation? Science. 1993;260:309-310.
37. Paulson EJ, Speck SH. Differential methylation of Epstein-Barr virus latency promoters facilitates viral persistence in healthy seropositive individuals. J Virol. 1999;73:9959-9968.
38. Chen J, Ueda K, Sakakibara S, et al. Activation of latent Kaposi's sarcoma-associated herpesvirus demethylation of the promoter of the lytic transactivator. Proc Natl Acad Sci USA. 2001;98:4119-4124.
39. Goodwin DJ, Walters MS, Smith PG, et al. The Herpesvirus saimiri Rta/ORF 50 protein reactivates the lytic replication cycle in a persistently infected A549 cell line. J Virol. 2001;75:4008-4013.
40. Lukac DM, Renne R, Kirshner JR, et al. Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. Virology. 1998;252:304-312.
41. Robertson KD, Hayward SD, Ling PD, et al. Transcriptional activation of the Epstein-Barr virus latency C promoter after 5-azacytidine treatment: evidence that demethylation at a single CpG site is crucial. Mol Cell Biol. 1995;15:6150-6159.
42. Schaefer BC, Strominger JL, Speck SH, et al. Host cell determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs. Mol Cell Biol. 1997;17:364-377.